Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (ZYME) is a clinical-stage biotechnology leader developing innovative bispecific antibodies and antibody-drug conjugates for oncology and autoimmune diseases. This page serves as the definitive source for ZYME news, providing investors and industry professionals with timely updates on therapeutic advancements and corporate developments.
Access consolidated updates including clinical trial milestones, regulatory filings, strategic partnerships, and financial results. Our curated collection features official press releases and verified news about ZYME's proprietary platforms like Azymetric™ and Albucore™, alongside collaborations with global biopharma leaders.
Key content categories include progress reports on novel cancer therapies, licensing agreements, scientific presentations, and pipeline expansion announcements. All materials maintain strict factual accuracy while avoiding speculative analysis to support informed decision-making.
Bookmark this page for efficient tracking of ZYME's advancements in multifunctional biotherapeutics. Check regularly for updates on their pioneering work in antibody engineering and targeted cancer treatment solutions.
Zymeworks Inc. (Nasdaq: ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW191, a novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). ZW191 targets FR⍺-expressing tumors, including ovarian, gynecological cancers, and non-small cell lung cancer (NSCLC). The drug incorporates a unique combination of antibody-linker stability and payload potency, with strong bystander activity.
Key features of ZW191 include:
- A drug-antibody ratio of eight for balanced tolerability and efficacy
- In-house generated FR⍺ monoclonal antibody for enhanced internalization
- Ability to target high, mid, and low levels of FR⍺ expression
- Robust anti-tumor activity and strong safety profile in preclinical models
Zymeworks, a clinical-stage biotech firm listed on Nasdaq under the symbol ZYME, will announce its Q2 2024 financial results after market close on August 1, 2024. The company develops novel biotherapeutics for hard-to-treat diseases. Following the financial release, Zymeworks' management will host a conference call and webcast at 4:30 pm ET on the same day to discuss the results and provide a corporate update. The webcast will be available live, with replays accessible on the Zymeworks website.
Zymeworks (Nasdaq: ZYME) announced that the FDA has cleared its investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody designed to treat mesothelin (MSLN)-expressing cancers such as ovarian cancer, non-small cell lung cancer, and mesothelioma.
ZW171 aims to improve upon current bispecific T-cell engagers by enhancing tumor selectivity and safety, demonstrating promising preclinical results.
The company plans to initiate clinical trials in 2024 and seek regulatory approval in other regions in the latter half of 2024, aligning with its ‘5 by 5’ strategy to advance additional therapies over the next two years.
ZW171 has shown potential to provide a more effective and tolerable treatment option, leveraging Zymeworks' Azymetric™ and EFECT™ technologies to enhance anti-tumor activity and safety.
Zymeworks announced the acceptance of the Biologics License Application (BLA) for zanidatamab by the National Medical Products Administration (NMPA) in China for second-line treatment of HER2-positive biliary tract cancer (BTC). This acceptance triggers an $8 million milestone payment from BeiGene, with potential for up to $164 million in future milestones and royalties on product sales. The application is based on data from the HERIZON-BTC-01 trial, showing a 41.3% objective response rate, a 12.9-month median duration of response, and a 5.5-month median progression-free survival. Additionally, the U.S. FDA recently accepted a BLA for zanidatamab for priority review, with a target action date of November 29, 2024. Zymeworks has already received $53 million in payments under its collaboration with BeiGene, not including the recent $8 million milestone.
Zymeworks, a clinical-stage biotechnology company focusing on novel biotherapeutics for difficult-to-treat diseases, has announced its participation in several upcoming investor conferences.
Management will engage in one-on-one meetings and presentations at these events:
1. Jefferies Global Healthcare Conference: June 5-6, with a fireside chat on June 5 at 10:30 am ET in New York.
2. Goldman Sachs 45th Annual Global Healthcare Conference: June 12 at 2:00 pm ET in Miami.
3. Citi’s 2024 European Healthcare Conference: Virtual one-on-one meetings on June 20.
Zymeworks Inc. reported $420.5 million in cash resources as of March 31, 2024, with projected funding into 2H 2027. They completed a BLA filing with the FDA for zanidatamab and plan a Phase 3 trial for breast cancer patients. The company also announced multiple IND submissions and abstract presentations at key oncology meetings. Revenue for Q1 2024 was $10.0 million, with a net loss of $31.7 million.
Zymeworks Inc. (ZYME) will be participating in the Bank of America Securities Health Care Conference and the J.P. Morgan Biotech Virtual Call Series on May 15th, 2024. The company is focused on developing innovative biotherapeutics to address challenging medical conditions.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
